AEMD missed EPS expectations by 5.82%
Aug 14, 2024, 11:31 PM
0.00%
What does AEMD do
Aethlon Medical Inc, based in San Diego, develops the Hemopurifier, a device aimed at treating cancer and viral infections by removing tumor-derived exosomes and various glycosylated viruses. The device targets conditions like HIV, HCV, Ebola, and multiple cancer types, focusing on both metastatic cancer treatment and life-threatening viruses without approved therapies.
Aethlon Medical Inc (AEMD) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Aethlon Medical Inc's actual EPS was -$0.34, missing the estimate of -$0.32 per share, resulting in a -5.82% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.